Phosphodiesterase type 5 inhibitors for premature ejaculation: advances in studies
Mo, D.-s.; Shang, X.-j.; Huang, Y.-f.
Zhonghua Nan Ke Xue 21(6): 561-565
2015
ISSN/ISBN: 1009-3591 PMID: 26242050 Document Number: 681765
Premature ejaculation (PE) is a common male sexual disorder with an incidence rate of 20-30%. Recent clinical trials have demonstrated that phosphodiesterase type 5 inhibitors (PDE5i), as the first-line drug for erectile dysfunction (ED), can improve ejaculatory function probably by acting on the peripheral and central adrenergic nerves. The possible action mechanisms of PDE5i may involve lessening of the central sympathetic output, modulation of the contractile responses from the vas deferens, seminal vesicles, prostate and urethra, induction of peripheral analgesia, and prolonging of the total erectile duration, increasing the confidence of ejaculation control, and reducing the post-ejaculation refractory time. This review discusses the possible mechanisms and clinical application of PDE5i in the treatment of PE.